Geneva Record, NP
Women's Health · Ringgold, GANPI 1003297078
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 167 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 20.4% — the pattern of someone who eats at a lot of different presentations. Among women's health clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 167 payments — averaging $20.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$696
- Sumitomo Pharma America, Inc.$375
- Pfizer$319
- AbbVie$252
- GSK$241
- Astellas Pharma US Inc$221
- plus $1K from 26 others
What the payments were for
- Food & beverage$3,390100%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 29 | $696 |
| Sumitomo Pharma America, Inc. | 10 | $375 |
| Pfizer | 21 | $319 |
| AbbVie | 14 | $252 |
| GSK | 14 | $241 |
| Astellas Pharma US Inc | 13 | $221 |
| Biohaven Pharmaceuticals, Inc. | 13 | $136 |
| Amgen | 9 | $128 |
| Kowa Pharmaceuticals America, Inc. | 1 | $125 |
| Dexcom, Inc. | 2 | $107 |
| Abbott | 5 | $95 |
| Heartflow, Inc. | 1 | $78 |
| E.r. Squibb & Sons, L.L.C. | 4 | $70 |
| Novartis | 3 | $54 |
| Boehringer Ingelheim | 3 | $52 |
| Xeris Pharmaceuticals, Inc. | 2 | $43 |
| Amarin Pharma, Inc. | 2 | $42 |
| Paratek Pharmaceuticals, Inc. | 2 | $40 |
| Bayer | 2 | $36 |
| AstraZeneca | 2 | $34 |
| Sanofi-aventis U.S. LLC | 2 | $31 |
| Inspire Medical Systems, Inc. | 2 | $29 |
| Johnson & Johnson | 1 | $29 |
| Lundbeck LLC | 1 | $29 |
| Jazz Pharmaceuticals Inc. | 1 | $24 |
| Sunovion Pharmaceuticals Inc. | 2 | $24 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $18 |
| Shield Therapeutics Inc | 1 | $17 |
| Boston Scientific | 1 | $16 |
| Medtronic | 1 | $16 |
| Daiichi Sankyo Inc. | 1 | $14 |
| Lilly USA, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,404 in reported general payments places this provider in the 95th percentile of 247 women's health providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 84 | $111,326 |
| OzempicSemaglutide | 57 | $89,480 |
| MounjaroTirzepatide | 56 | $58,955 |
| RybelsusSemaglutide | 32 | $41,451 |
| EliquisApixaban | 26 | $36,165 |
| TrulicityDulaglutide | 22 | $24,045 |
| Tresiba Flextouch U-200Insulin Degludec | 24 | $19,603 |
| JanuviaSitagliptin Phosphate | 27 | $18,410 |
| LinzessLinaclotide | 14 | $11,333 |
| Repatha SureclickEvolocumab | 18 | $9,629 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $7,672 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 12 | $5,920 |
| Rosuvastatin Calcium | 195 | $2,706 |
| Atorvastatin Calcium | 312 | $2,661 |
| Losartan Potassium | 236 | $2,290 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $696 | $130,93189 claims |
| Boehringer IngelheimJardiance | $52 | $111,32684 claims |
| Lilly USA, LLCMounjaro, Trulicity | $14 | $83,00078 claims |
| PfizerEliquis | $319 | $36,16526 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $241 | $13,59224 claims |
| AbbVieLinzess | $252 | $11,33314 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 247 women's health providers in Georgia.
Other women's health in Ringgold
- Sherri SellersSavannah$94K
- Jaclyn PiastaMarietta$8K
- Angela HurstMoultrie$5K
- Laurie RayAtlanta$5K
- Heather Thomas-OsuntokunAtlanta$3K
- Ania KirollosChamblee$3K
- Katie SellsSnellville$3K
- Susan AbbottAtlanta$3K
- Labrittany DavisAtlanta$3K
- Gretchen EichenlaubSavannah$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.